Noam A VanderWalde1, Anne Marie Meyer2, Allison M Deal2, J Bradley Layton3, Huan Liu2, William R Carpenter4, Mark C Weissler5, David N Hayes6, Mary E Fleming1, Bhishamjit S Chera7. 1. Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 3. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 4. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 5. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 6. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 7. Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: bchera@med.unc.edu.
Abstract
PURPOSE: The purpose of this study was to compare chemoradiation therapy (CRT) with radiation therapy (RT) only in an older patient population with head and neck squamous cell carcinoma (HNSCC). METHODS AND MATERIALS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database (1992-2007), we identified a retrospective cohort of nonmetastatic HNSCC patients and divided them into treatment groups. Comparisons were made between CRT and RT cohorts. Propensity scores for CRT were estimated from covariates associated with receipt of treatment using multivariable logistic regression. Standardized mortality ratio weights (SMRW) were created from the propensity scores and used to balance groups on measured confounders. Multivariable and SMR-weighted Cox proportional hazard models were used to estimate the hazard ratio (HR) of death for receipt of CRT versus RT among the whole group and for separate patient and tumor categories. RESULTS: The final cohort of 10,599 patients was 68% male and 89% white. Median age was 74 years. Seventy-four percent were treated with RT, 26% were treated with CRT. Median follow-up points for CRT and RT survivors were 4.6 and 6.3 years, respectively. On multivariable analysis, HR for death with CRT was 1.13 (95% confidence interval [CI]: 1.07-1.20; P<.01). Using the SMRW model, the HR for death with CRT was 1.08 (95% CI: 1.02-1.15; P=.01). CONCLUSIONS: Although the addition of chemotherapy to radiation has proven efficacious in many randomized controlled trials, it may be less effective in an older patient population treated outside of a controlled trial setting.
PURPOSE: The purpose of this study was to compare chemoradiation therapy (CRT) with radiation therapy (RT) only in an older patient population with head and neck squamous cell carcinoma (HNSCC). METHODS AND MATERIALS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database (1992-2007), we identified a retrospective cohort of nonmetastatic HNSCC patients and divided them into treatment groups. Comparisons were made between CRT and RT cohorts. Propensity scores for CRT were estimated from covariates associated with receipt of treatment using multivariable logistic regression. Standardized mortality ratio weights (SMRW) were created from the propensity scores and used to balance groups on measured confounders. Multivariable and SMR-weighted Cox proportional hazard models were used to estimate the hazard ratio (HR) of death for receipt of CRT versus RT among the whole group and for separate patient and tumor categories. RESULTS: The final cohort of 10,599 patients was 68% male and 89% white. Median age was 74 years. Seventy-four percent were treated with RT, 26% were treated with CRT. Median follow-up points for CRT and RT survivors were 4.6 and 6.3 years, respectively. On multivariable analysis, HR for death with CRT was 1.13 (95% confidence interval [CI]: 1.07-1.20; P<.01). Using the SMRW model, the HR for death with CRT was 1.08 (95% CI: 1.02-1.15; P=.01). CONCLUSIONS: Although the addition of chemotherapy to radiation has proven efficacious in many randomized controlled trials, it may be less effective in an older patient population treated outside of a controlled trial setting.
Authors: Zachary S Zumsteg; Benjamin H Lok; Allen S Ho; Esther Drill; Zhigang Zhang; Nadeem Riaz; Stephen L Shiao; Jennifer Ma; Sean M McBride; C Jillian Tsai; Shrujal S Baxi; Eric J Sherman; Nancy Y Lee Journal: Cancer Date: 2016-12-16 Impact factor: 6.860
Authors: Sheela Hanasoge; Kelly R Magliocca; Jeffrey M Switchenko; Nabil F Saba; J Trad Wadsworth; Mark W El-Deiry; Dong M Shin; Fadlo Khuri; Jonathan J Beitler; Kristin A Higgins Journal: Head Neck Date: 2015-07-30 Impact factor: 3.147
Authors: Ronald Maggiore; Zachary S Zumsteg; Karlynn BrintzenhofeSzoc; Kelly M Trevino; Ajeet Gajra; Beatriz Korc-Grodzicki; Joel B Epstein; Stewart M Bond; Ira Parker; Julie A Kish; Barbara A Murphy; Noam A VanderWalde Journal: Int J Radiat Oncol Biol Phys Date: 2017-07-15 Impact factor: 7.038
Authors: Jan Stuk; Jaroslav Vanasek; Karel Odrazka; Martin Dolezel; Iveta Kolarova; Ales Hlavka; Martina Vitkova; Jan Vodicka; Karel Pokorny Journal: Rep Pract Oncol Radiother Date: 2019-11-12
Authors: Erik Haehl; Alexander Rühle; Hélène David; Tobias Kalckreuth; Tanja Sprave; Raluca Stoian; Christoph Becker; Andreas Knopf; Anca-Ligia Grosu; Nils H Nicolay Journal: Radiat Oncol Date: 2020-02-04 Impact factor: 3.481
Authors: Erik Haehl; Alexander Rühle; Simon Spohn; Tanja Sprave; Eleni Gkika; Constantinos Zamboglou; Anca-Ligia Grosu; Nils H Nicolay Journal: Front Oncol Date: 2022-01-03 Impact factor: 6.244
Authors: Jens Müller von der Grün; Daniel Martin; Timo Stöver; Shahram Ghanaati; Claus Rödel; Panagiotis Balermpas Journal: Biomed Res Int Date: 2018-01-17 Impact factor: 3.411